» Articles » PMID: 32458502

Glycyrrhetinic Acid and Its Derivatives As Potential Alternative Medicine to Relieve Symptoms in Nonhospitalized COVID-19 Patients

Overview
Journal J Med Virol
Specialty Microbiology
Date 2020 May 28
PMID 32458502
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

SARS-CoV-2 is highly infectious, and infection by this virus results in COVID-19, manifesting predominantly symptoms in the lower respiratory system. Detection of viral genomic materials by RT-PCR is the gold standard for diagnosis. Suspected COVID-19 patients who had a documented history of exposure and exhibited symptoms, but did not have positive PCR test results, were generally self-quarantined with prescriptions aiming to help attenuate their symptoms. These prescriptions are however neither specific nor highly effective for COVID-19 treatment. Given the rapidly growing pandemic and the overwhelmed medical system, the number of self-quarantined patients is increasing. There is an urgent need of alternative medicine to help patients relieve symptoms during self-quarantine, and to potentially help increase their chances of survival and recovery from the infection. We report here a case of severe COVID-19 that never had a positive PCR test result during disease progression but was confirmed with antibody test post recovery. This patient was self-quarantined and received diammonium glycyrrhizinate (DG), a steroid-like molecule, in combination with vitamin C as alternative medicine. This patient went through severe COVID-19 but eventually recovered upon the implementation of this treatment regimen, suggesting potential therapeutic effects of DG as alternative medicine to help relieve COVID-19 symptoms.

Citing Articles

Amorphous Solid Dispersions of Glycyrrhetinic Acid: Using Soluplus, PVP, and PVPVA as the Polymer Matrix to Enhance Solubility, Bioavailability, and Stability.

Zhao M, Shi X, Chang J, Wang R, Zhou J, Liu P AAPS PharmSciTech. 2024; 26(1):18.

PMID: 39707118 DOI: 10.1208/s12249-024-03007-1.


Investigating the effect of echinacea extraction syrup on the outcomes of lower respiratory infections in patients with COVID-19: a randomized clinical trial study.

Kheirandish E, Mahdizadeh M, Mahdizadeh M, Rezaeitalab F, Yousefi M, Shojaee S Virol J. 2024; 21(1):319.

PMID: 39702335 PMC: 11656726. DOI: 10.1186/s12985-024-02586-6.


A review of typical biological activities of glycyrrhetinic acid and its derivatives.

Chen L, Gong J, Yong X, Li Y, Wang S RSC Adv. 2024; 14(10):6557-6597.

PMID: 38390501 PMC: 10882267. DOI: 10.1039/d3ra08025k.


Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial.

Zendejas-Hernandez U, Alcantara-Martinez N, Vivar D, Valenzuela F, Sosa Espinoza A, Cervera Ceballos E Front Immunol. 2024; 14:1282280.

PMID: 38283346 PMC: 10811189. DOI: 10.3389/fimmu.2023.1282280.


Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies.

Yin S, Klaeger S, Chea V, Carulli I, Rachimi S, Black K Front Immunol. 2023; 14:1269335.

PMID: 37942334 PMC: 10628763. DOI: 10.3389/fimmu.2023.1269335.


References
1.
Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

2.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

3.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

4.
Cao X . COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020; 20(5):269-270. PMC: 7143200. DOI: 10.1038/s41577-020-0308-3. View

5.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View